2004 INTERCEPT Conference Abstracts
- Vesole D, Stadtmauer E, Goodnough LT et al for the SPRINT Study Group. Source of donor stem cells impacts incidence of bleeding and platelet and RBC transfusion requirements during stem cell transplantation (SCT): results of the phase III SPRINT trial of INTERCEPT pathogen-inactivated platelets.
- Sawyer L, Dupuis K, Sampson-Johannes A et al. Helinx technology inactivates high titers of SARS-CoV, WNV and Vaccinia in platelet concentrates.
Conlan MG, Corash L, Flament J et al for the euroSPRITE, SPRINT and STEP Study Groups. INTERCEPT Platelets & Plasma do not result in neoantigenicity: results of 7 phase 3 clinical trials.
Donnelly B, Sawyer L, Lin L. Similar in vitro function and bacterial inactivation, leukoreduced (Lr) vs non-Lr INTERCEPT Platelets.
Dupuis K, Sampson-Johannes A, Bernard K. Helinx® technology inactivates high titers of SARS-CoV, WNV and Vaccinia in INTERCEPT Platelets.
- Sullivan T, McCullough T. Assessment of safety for the INTERCEPT® Blood System for platelets in neonatal preclinical model.
Chen C, Donnelly B, Blair A et al. INTERCEPT Platelets from Haemonetics MCS+ ® and Cobe Spectra demonstrate pathogen inactivation, retain function, and meet Council of Europe standards.
Chen D, Donnelly B, Taga T et al. INTERCEPT Platelets from Trima collection system retain function, demonstrate inactivation of key pathogens, and meet Council of Europe standards.
- Dupuis K, Sampson-Johannes A, Bernard K et al. Helinx® technology inactivates high titers of SARS-CoV, WNV and Vaccinia in platelet concentrates.
- Hanson D, Dupuis K, Sawyer L. Inactivation of Parvovirus B19 in platelets by Helinx® technology.
Benoit Y, Van Haute I, Vandecruys E et al. Safety and efficacy of pathogen-inactivated platelets transfused in routine use to pediatric patients: an interim report.
Moeremans K, Warie H, Annemans L et al. Assessment of the economic value of the INTERCEPT Blood System for platelets in Belgium.
- Osselaer JC, Doyen D, Sonet A et al. Routine use of platelet components prepared with photochemical treatment (INTERCEPT Platelets): impact on clinical outcomes and costs.